MCID: GST111
MIFTS: 20

Gastroenteropancreatic Neuroendocrine Neoplasm

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Gastroenteropancreatic Neuroendocrine Neoplasm

MalaCards integrated aliases for Gastroenteropancreatic Neuroendocrine Neoplasm:

Name: Gastroenteropancreatic Neuroendocrine Neoplasm 59
Gep-Nen 59

Classifications:

Orphanet: 59  
Rare endocrine diseases


External Ids:

Orphanet 59 ORPHA100092

Summaries for Gastroenteropancreatic Neuroendocrine Neoplasm

MalaCards based summary : Gastroenteropancreatic Neuroendocrine Neoplasm, also known as gep-nen, is related to neuroendocrine tumor and neuroendocrine carcinoma. An important gene associated with Gastroenteropancreatic Neuroendocrine Neoplasm is CHGA (Chromogranin A). The drugs Octreotide and Gastrointestinal Agents have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and lung.

Related Diseases for Gastroenteropancreatic Neuroendocrine Neoplasm

Diseases related to Gastroenteropancreatic Neuroendocrine Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 neuroendocrine tumor 10.8
2 neuroendocrine carcinoma 10.7
3 adenocarcinoma 10.4
4 carcinoid syndrome 10.3
5 familial adenomatous polyposis 10.1
6 large cell neuroendocrine carcinoma 10.1
7 gastrointestinal carcinoma 10.1
8 gastrointestinal system cancer 10.1
9 hyperglycemia 10.1
10 gastrointestinal system disease 10.1
11 48,xyyy 10.1
12 neuroendocrine neoplasm of appendix 10.1
13 gastric adenocarcinoma 9.7 MGMT CHGA
14 gastric leiomyoma 9.6 MGMT CHGA
15 pleomorphic xanthoastrocytoma 9.4 MGMT CHGA

Graphical network of the top 20 diseases related to Gastroenteropancreatic Neuroendocrine Neoplasm:



Diseases related to Gastroenteropancreatic Neuroendocrine Neoplasm

Symptoms & Phenotypes for Gastroenteropancreatic Neuroendocrine Neoplasm

Drugs & Therapeutics for Gastroenteropancreatic Neuroendocrine Neoplasm

Drugs for Gastroenteropancreatic Neuroendocrine Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
2 Gastrointestinal Agents Phase 2
3 Pharmaceutical Solutions Phase 2
4 Antineoplastic Agents, Hormonal Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients Recruiting NCT03422029 Phase 2 177Lu-Dotatate PRRT
2 Identification of Biomarker Profiles for Individualized Prognostic Stratification and Therapy in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia (GEP-NEN) Unknown status NCT02838862

Search NIH Clinical Center for Gastroenteropancreatic Neuroendocrine Neoplasm

Genetic Tests for Gastroenteropancreatic Neuroendocrine Neoplasm

Anatomical Context for Gastroenteropancreatic Neuroendocrine Neoplasm

MalaCards organs/tissues related to Gastroenteropancreatic Neuroendocrine Neoplasm:

41
Liver, Brain, Lung, Small Intestine

Publications for Gastroenteropancreatic Neuroendocrine Neoplasm

Articles related to Gastroenteropancreatic Neuroendocrine Neoplasm:

(show top 50) (show all 77)
# Title Authors PMID Year
1
Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis. 38
31328428 2019
2
Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies. 38
31368038 2019
3
[Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)]. 38
30969346 2019
4
Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts. 38
31077609 2019
5
Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome. 38
30991982 2019
6
Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin. 38
30867449 2019
7
Nutritional and vitamin status in patients with neuroendocrine neoplasms. 38
30886501 2019
8
BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma. 38
30144031 2019
9
The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs. 38
30796708 2019
10
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. 38
30540557 2019
11
Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). 38
30153658 2019
12
Lung Metastases in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms: An Appraisal of the Validity of Thoracic Imaging Surveillance. 38
30673674 2019
13
PDGFRα expression as a novel therapeutic marker in well-differentiated neuroendocrine tumors. 38
30346879 2019
14
The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE. 38
31091247 2019
15
Spatio-temporal image correlation (STIC) in evaluation of advanced neuroendocrine tumours. 38
30633319 2019
16
Clinicopathologic Characteristics and Survival of Patients with Gastroenteropancreatic Neuroendocrine Neoplasm in a Multi-Ethnic Asian Institution. 38
30399612 2019
17
LncNEN885 inhibits epithelial-mesenchymal transition by partially regulation of Wnt/β-catenin signalling in gastroenteropancreatic neuroendocrine neoplasms. 38
30033597 2018
18
Value of hepatocellular phase imaging after intravenous gadoxetate disodium for assessing hepatic metastases from gastroenteropancreatic neuroendocrine tumors: comparison with other MRI pulse sequences and with extracellular agent. 38
29470627 2018
19
Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms. 38
29970506 2018
20
Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. 38
29387927 2018
21
Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm. 38
29940892 2018
22
Associations between Single Nucleotide Polymorphisms in the Mitochondrial DNA D-Loop Region and Outcome of Gastroenteropancreatic Neuroendocrine Neoplasm. 38
29970437 2018
23
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). 38
29511910 2018
24
Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. 38
29237387 2018
25
[Neuroendocrine tumors of the abdomen]. 38
29234821 2018
26
Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors. 38
28910819 2018
27
The Risk of Second Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Nationwide Population-Based Study. 38
30092588 2018
28
Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose? 38
29256148 2017
29
Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. 38
28949958 2017
30
A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. 38
29069739 2017
31
[Consensus and controversy of endoscopic diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors]. 38
28900987 2017
32
Identification of sequence polymorphisms in the displacement loop region of mitochondrial DNA as a risk factor for gastroenteropancreatic neuroendocrine neoplasm. 38
27704598 2017
33
Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. 38
28522174 2017
34
[Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms]. 38
28900990 2017
35
[Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms]. 38
28900988 2017
36
[Consensus and controversy on subtype classification of gastric neuroendocrine neoplasms]. 38
28900986 2017
37
Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. 38
28637502 2017
38
Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE. 38
27743210 2017
39
Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria. 38
28334622 2017
40
Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms. 38
28454409 2017
41
Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? 38
28487601 2017
42
[Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms]. 38
28338171 2017
43
Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. 38
28454229 2017
44
[Standardization for diagnostic tumor pathology: gastroenteropancreatic neuroendocrine neoplasm]. 38
28173663 2017
45
Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease. 38
27513674 2017
46
Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia. 38
28039474 2017
47
Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms. 38
29232390 2017
48
Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. 38
27636009 2016
49
[Implementation of multidisciplinary team in the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasm]. 38
27928786 2016
50
Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification. 38
27833387 2016

Variations for Gastroenteropancreatic Neuroendocrine Neoplasm

Expression for Gastroenteropancreatic Neuroendocrine Neoplasm

Search GEO for disease gene expression data for Gastroenteropancreatic Neuroendocrine Neoplasm.

Pathways for Gastroenteropancreatic Neuroendocrine Neoplasm

GO Terms for Gastroenteropancreatic Neuroendocrine Neoplasm

Sources for Gastroenteropancreatic Neuroendocrine Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....